Publications by authors named "Jeanne E Hendrickson"

Article Synopsis
  • - Hyperviscosity syndrome (HVS) is a condition caused by increased blood thickness, which can occur due to factors like hypergammaglobulinemia.
  • - Cases of HVS linked to IgA multiple myeloma are rare, and while the removal of other immunoglobulins by therapeutic plasma exchange (TPE) is well understood, IgA's removal isn't as clear.
  • - The report discusses a patient with HVS from IgA myeloma who underwent two TPE treatments, resulting in noticeable improvements in symptoms, IgA levels, and blood viscosity.
View Article and Find Full Text PDF
Article Synopsis
  • * Data was analyzed from 120 patients, revealing that most aimed for high collection goals, with notable challenges for older patients and those with low platelet counts affecting their success rates.
  • * Recommendations for improvement included adjusting collection goals, modifying medication timing, using platelet counts to predict outcomes, and optimizing scheduling to accommodate more patients efficiently.
View Article and Find Full Text PDF

Transfusion of red blood cells (RBCs) can be lifesaving for individuals living with sickle cell disease (SCD). However, alloimmunization following transfusion is more common with SCD than other patient populations, resulting in morbidity and mortality. Management of complications related to RBC alloantibodies, including delayed hemolytic transfusion reactions (DHTRs) and identifying compatible RBCs for future transfusions, remains a challenge for hematologists and transfusion medicine providers.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to develop automated tools for actively monitoring errors in pediatric blood management (PBM) rather than relying on passive methods.
  • An expert panel identified 28 triggers for errors, leading to the creation of 5 automated tools, which were tested using electronic health record data over four years.
  • Findings showed that first transfusions without patient identification were common near misses, and over-transfusions were identified as a significant source of harm in pediatric care.
View Article and Find Full Text PDF
Article Synopsis
  • Red blood cell alloimmunization leads to a high rate of delayed hemolytic transfusion reactions (DHTRs) and associated mortality in sickle cell disease (SCD) patients, but a shared transfusion resource can significantly reduce these risks. * A Markov cohort simulation study found that implementing this resource in the U.S. could decrease DHTR-specific mortality by 26%, resulting in 4,000 additional quality-adjusted life years (QALYs) at an incremental cost of $300 million, showing a cost-effectiveness of $75,600/QALY. * The effectiveness of such a resource is contingent on having a sufficient patient population (at least 1,819) and an annual cost not exceeding $
View Article and Find Full Text PDF

Background: Anemia in very low birth weight (VLBW) infants is common and frequently managed with red blood cell (RBC) transfusions. We utilized a linked vein-to-vein database to assess the role of blood donors and component factors on measures of RBC transfusion effectiveness in VLBW infants.

Study Design And Methods: We linked blood donor and component manufacturing data with VLBW infants transfused RBCs between January 1, 2013 and December 31, 2016 in the Recipient Epidemiology Donor Evaluation Study-III (REDS III) database.

View Article and Find Full Text PDF

Patients with sickle cell disease (SCD) are considered to be immunocompromised, yet data on the antibody response to SARS-CoV-2 vaccination in SCD is limited. We investigated anti-SARS-CoV-2 IgG titres and overall neutralizing activity in 201 adults with SCD and demographically matched non-SCD controls. Unexpectedly, patients with SCD generate a more robust and durable COVID-19 vaccine IgG response compared to matched controls, though the neutralizing activity remained similar across both cohorts.

View Article and Find Full Text PDF

Hyperhaemolysis syndrome (HHS), a severe form of delayed haemolytic transfusion reaction most commonly described in patients with sickle cell disease (SCD), involves destruction of both donor and recipient red blood cells (RBCs). As the epidemiology and underlying pathophysiology have yet to be definitively elucidated, recognition can be challenging. We systematically reviewed PubMed and EMBASE to identify all cases of post-transfusion hyperhaemolysis and characterized the epidemiological, clinical and immunohaematological characteristics and treatments of HHS.

View Article and Find Full Text PDF

Background: Due to platelet availability limitations, platelet units ABO mismatched to recipients are often transfused. However, since platelets express ABO antigens and are collected in plasma which may contain ABO isohemagglutinins, it remains controversial as to whether ABO non-identical platelet transfusions could potentially pose harm and/or have reduced efficacy.

Study Design And Methods: The large 4-year publicly available Recipient Epidemiology and Donor Evaluation Study-III (REDS-III) database was used to investigate patient outcomes associated with ABO non-identical platelet transfusions.

View Article and Find Full Text PDF

Background: Studies of human patients have shown that most anti-RBC alloantibodies are IgG1 or IgG3 subclasses, although it is unclear why transfused RBCs preferentially drive these subclasses over others. Though mouse models allow for the mechanistic exploration of class-switching, previous studies of RBC alloimmunization in mice have focused more on the total IgG response than the relative distribution, abundance, or mechanism of IgG subclass generation. Given this major gap, we compared the IgG subclass distribution generated in response to transfused RBCs relative to protein in alum vaccination, and determined the role of STAT6 in their generation.

View Article and Find Full Text PDF

Background: Studies of human patients have shown that most anti-RBC alloantibodies are IgG1 or IgG3 subclasses, though it is unclear why transfused RBCs preferentially drive these subclasses over others. Though mouse models allow for the mechanistic exploration of class-switching, previous studies of RBC alloimmunization in mice have focused more on the total IgG response than the relative distribution, abundance, or mechanism of IgG subclass generation. Given this major gap, we compared the IgG subclass distribution generated in response to transfused RBCs relative to protein in alum vaccination, and determined the role of STAT6 in their generation.

View Article and Find Full Text PDF

Introduction: The impact of blood storage on red blood cell (RBC) alloimmunization remains controversial, with some studies suggesting enhancement of RBC-induced alloantibody production and others failing to observe any impact of storage on alloantibody formation. Since evaluation of storage on RBC alloimmunization in patients has examined antibody formation against a broad range of alloantigens, it remains possible that different clinical outcomes reflect a variable impact of storage on alloimmunization to specific antigens.

Methods: RBCs expressing two distinct model antigens, HEL-OVA-Duffy (HOD) and KEL, separately or together (HOD × KEL), were stored for 0, 8, or 14 days, followed by detection of antigen levels prior to transfusion.

View Article and Find Full Text PDF
Article Synopsis
  • Antibodies against red blood cell alloantigens can lead to serious health issues for patients receiving transfusions, with some individuals showing high rates of alloimmunization while others do not.
  • Research indicates that CD4 T-cells, which typically recognize surface antigens on RBCs, can also respond to intracellular antigens, potentially affecting the immune response during transfusions.
  • In a study using mice, it was shown that prior exposure to intracellular RBC antigens can enhance the likelihood of forming antibodies against separate surface antigens from future transfusions, highlighting a new factor in understanding alloimmunization risks.
View Article and Find Full Text PDF

Passive immunization with anti-D can prevent maternal alloimmunization to RhD thereby preventing hemolytic disease of the fetus and newborn. Unexpectedly, anti-D fails in some cases and some monoclonal anti-D preparations paradoxically enhances alloimmunization. The underlying mechanisms modulating humoral alloimmunization by anti-D are unknown.

View Article and Find Full Text PDF

Background: In 2019 the Centers for Disease Control and Prevention (CDC) reported a series of 4 transfusion reactions that resulted from contamination of apheresis platelet products. Products involved in all 4 cases were contaminated with Acinetobacter calcoaceticus-baumannii complex (ACBC) and in 3 products Staphylococcus saprophyticus was found as well. CDC investigation found that bacterial isolates from the cases were genetically related and suggested a common source of contamination.

View Article and Find Full Text PDF

Haemolytic disease of the newborn (HDN) can be associated with significant morbidity. Prompt treatment with intensive phototherapy (PT) and exchange transfusions (ETs) can dramatically improve outcomes. ET is invasive and associated with risks.

View Article and Find Full Text PDF

Patients with sickle cell disease (SCD) have a high prevalence of RBC alloimmunization. However, underlying mechanisms are poorly understood. Given that proinflammatory type 1 interferons (IFN/) and interferon stimulated genes (ISGs) promote alloimmunization in mice, we hypothesized that IFN/ may contribute to the increased frequency of alloimmunization in patients with SCD.

View Article and Find Full Text PDF
Article Synopsis
  • RBC transfusion therapy is crucial for treating anemia, but it can lead to complications like the development of non-ABO alloantibodies due to unclear mechanisms.
  • Research indicates that storing mouse RBCs increases their ability to trigger immune responses, particularly through activation of splenic dendritic cells (DCs).
  • Findings show that the activation of DCs and the resulting antibody response require the MyD88 adapter molecule in TLR signaling, rather than TRIF, highlighting specific pathways for detecting transfused RBCs and initiating immune responses.
View Article and Find Full Text PDF

Recent advancements in infectious disease testing methods and pathogen reduction technologies have greatly reduced the incidence of microbial contamination of allogeneic blood products. Despite this significant reduction, contamination of autologous cellular therapy products remains a challenging issue, as many of these mitigation strategies are not feasible for such products. Most microorganisms isolated from cellular therapy products are Gram-positive normal skin flora, and studies have demonstrated that adverse effects are infrequent when these contaminated products are infused.

View Article and Find Full Text PDF

Importance: There is clinical equipoise for COVID-19 convalescent plasma (CCP) use in patients hospitalized with COVID-19.

Objective: To determine the safety and efficacy of CCP compared with placebo in hospitalized patients with COVID-19 receiving noninvasive supplemental oxygen.

Design, Setting, And Participants: CONTAIN COVID-19, a randomized, double-blind, placebo-controlled trial of CCP in hospitalized adults with COVID-19, was conducted at 21 US hospitals from April 17, 2020, to March 15, 2021.

View Article and Find Full Text PDF